ArticleOncoimmunology2012
Tumor cells, rather than dendritic cells, deliver antigen to the lymph node for cross-presentation.
Article in Oncoimmunology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 23 citations in OpenAlex.
- Sentinel lymph node detection for lung cancer surgery: a possible pathological surrogate of overall lymph node dissection.Frontiers in oncology · 2025Article
- Sentinel Lymph Node in Non-Small Cell Lung Cancer: Assessment of Feasibility and Safety by Near-Infrared Fluorescence Imaging and Clinical Consequences.Journal of personalized medicine · 2022Article
- Comparison of recurrence risk between patients with clinically node-positive and -negative stage I non-small cell lung cancer following surgery: A propensity score matching analysis.Thoracic cancer · 2022Article
- Tumour draining lymph node-generated CD8 T cells play a role in controlling lung metastases after a primary tumour is removed but not when adjuvant immunotherapy is used.Cancer immunology, immunotherapy : CII · 2021Article
- Clinical Efficacy and Future Prospects of Immunotherapy in Lung Cancer.Life (Basel, Switzerland) · 2021Review
- Predicted limited redistribution of T cells to secondary lymphoid tissue correlates with increased risk of haematological malignancies in asplenic patients.Scientific reports · 2021Article
- Leveraging Endogenous Dendritic Cells to Enhance the Therapeutic Efficacy of Adoptive T-Cell Therapy and Checkpoint Blockade.Frontiers in immunology · 2020Review
- The role and therapeutic implications of T cells in cancer of the lung.Clinical & translational immunology · 2019Article
- The Biology and Underlying Mechanisms of Cross-Presentation of Exogenous Antigens on MHC-I Molecules.Annual review of immunology · 2017Review
- Strong spontaneous tumor neoantigen responses induced by a natural human carcinogen.Oncoimmunology · 2015Article
- Restoration of defective cross-presentation in tumors by gemcitabine.Oncoimmunology · 2015Article
- Immunosuppressive Mechanisms of Malignant Gliomas: Parallels at Non-CNS Sites.Frontiers in oncology · 2015Review
- The "Trojan Horse" approach to tumor immunotherapy: targeting the tumor microenvironment.Journal of immunology research · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It is widely accepted that generation of tumor specific CD8+ T-cell responses occur via cross-priming; however the source of tumor antigen for this event is unknown. We examined the source and form of tumor antigen required for cross-presentation in the local lymph node (LN) using a syngeneic mouse tumor model expressing a marker antigen. We found that cross-presentation of this model tumor antigen in the LN is dependent on continuous traffic of antigen from the tumor site, but without any detectable migration of tumor resident dendritic cells (DCs). Instead, small numbers of tumor cells metastasize to local LNs where they are exposed to a localized CTL attack, resulting in delivery of tumor antigen into the cross-presentation pathway.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.